UroGen Earnings Reports

UroGen's Q4 2024 revenue reached $24.6 million, reflecting a 5% year-over-year increase driven by higher JELMYTO demand. The company posted a net loss of $37.5 million due to increased R&D and SG&A expenses. JELMYTO continues to see growth in new patient starts and prescribers, and UroGen remains focused on advancing its UGN-102 NDA submission and pipeline assets.

UroGen Pharma reported JELMYTO net product revenues of $25.2 million for Q3 2024, compared to $20.9 million for Q3 2023. The FDA accepted the New Drug Application for UGN-102, with a PDUFA target action date set for June 13, 2025. As of September 30, 2024, the company had $254.2 million in cash, cash equivalents, and marketable securities.

UroGen Pharma reported JELMYTO net product revenues of $21.8 million for Q2 2024 and ended the quarter with $241.3 million in cash, cash equivalents, and marketable securities. The company is focused on completing the NDA submission for UGN-102 and preparing for its potential approval and launch.

UroGen Pharma reported Q1 2024 financial results, highlighted by JELMYTO net product revenues of $18.8 million, a 10% increase compared to Q1 2023. The company is advancing its pipeline, with UGN-102 nearing NDA completion and UGN-103's IND accepted by the FDA.

UroGen Pharma reported JELMYTO net product revenues of $23.5 million for Q4 2023, compared to $18.1 million for the same period in 2022. The company also initiated the submission of a rolling NDA to the FDA for UGN-102.

UroGen Pharma reported JELMYTO® net product revenues of $20.9 million in Q3 2023, representing approximately 30% growth compared to the same period last year. The company is also preparing for a rolling NDA submission for UGN-102, planned for January 2024.

UroGen Pharma reported record JELMYTO quarterly sales of $21.1 million, a ~27% increase from the same period last year. Both ENVISION and ATLAS Phase 3 trials of UGN-102 met their primary endpoints. The company also completed a $120 million private placement of ordinary shares and pre-funded warrants.

UroGen Pharma reported a net product revenue of $17.2 million for JELMYTO in Q1 2023, representing a ~27% increase compared to Q1 2022. The company is preparing for topline results from the ENVISION and ATLAS clinical trials and anticipates submitting an NDA for UGN-102 in 2024.

UroGen Pharma reported JELMYTO net product revenues of $18.1 million for Q4 2022, compared to $16.2 million for the same period in 2021. The company also completed enrollment of the ENVISION Phase 3 pivotal clinical trial for UGN-102 for LG-IR-NMIBC and anticipates topline data readout from the ATLAS clinical study and complete response from the ENVISION pivotal study in mid-year 2023.

UroGen Pharma reported its Q3 2022 financial results, highlighting a 41% increase in JELMYTO® net product revenue compared to the same period last year, reaching $16.1 million. The FDA authorized an extension of the in-use period for JELMYTO® admixture, and the company is progressing with its UGN-102 Phase 3 pivotal trial.

UroGen Pharma reported a net product revenue of $16.6 million for Q2 2022, a 28% increase year-over-year. The company is on track with its clinical development programs, including the UGN-102 Phase 3 trial and UGN-301 Phase 1 clinical trial. They are focused on reaching cash flow break-even in 2025 while strategically deploying capital.

UroGen Pharma reported first quarter 2022 financial results, highlighted by an 81% increase in Jelmyto net product revenue compared to Q1 2021, reaching $13.6 million. The company also progressed its clinical programs with the ongoing Phase 3 ENVISION trial for UGN-102 and the initiation of a Phase 1 clinical trial for UGN-301.

UroGen Pharma reported a net product revenue of $16.2 million for Q4 2021 from Jelmyto, representing a 42% increase over the previous quarter. The company also announced an up to $100 million senior secured term loan facility to support operations to reach cash flow breakeven by 2025.

UroGen Pharma reported Q3 2021 financial results, with Jelmyto net product revenue of $11.4 million, representing over 200% growth compared to Q3 2020. The company is initiating a new single-arm Phase 3 study of UGN-102 and is pleased with the strong demand for Jelmyto.

UroGen Pharma reported a net product revenue of $13.0 million for Jelmyto in the second quarter of 2021, representing a 70% growth over the first quarter. The company's Phase 3 ATLAS trial for UGN-102 continues to enroll patients, with nearly 100 global centers activated. UroGen also commenced Jelmyto geographic expansion efforts with a Neopharm license in Israel.

UroGen Pharma reported a net product revenue of $7.5 million for Jelmyto in Q1 2021. The company is progressing with its Phase 3 ATLAS trial and expanding its immuno-oncology pipeline through strategic collaborations. They also had a net loss of $25.9 million.

UroGen Pharma reported financial results for the fourth quarter and full year ended December 31, 2020. The company achieved Jelmyto net product revenue of $8.0 million for the fourth quarter. The Phase 3 ATLAS trial for UGN-102 was initiated and is actively enrolling patients.

UroGen Pharma reported Jelmyto net product revenue of $3.5 million in the third quarter of 2020, its first full quarter of commercialization. The company's research and development expenses were $10.2 million, and SG&A expenses were $22.1 million. UroGen reported a net loss of $28.8 million, or $1.31 per share, and cash and cash equivalents totaled $125.5 million as of September 30, 2020.

UroGen Pharma reported net product sales of Jelmyto of approximately $371,500 for the second quarter ended June 30, 2020. The company's cash, cash equivalents and marketable securities totaled $151.6 million as of June 30, 2020.